TY - JOUR AU - Noro, Rintaro AU - Gemma, Akihiko AU - Kosaihira, Seiji AU - Kokubo, Yutaka AU - Chen, Mingwei AU - Seike, Masahiro AU - Kataoka, Kiyoko AU - Matsuda, Kuniko AU - Okano, Tetsuya AU - Minegishi, Yuji AU - Yoshimura, Akinobu AU - Kudoh, Shoji PY - 2006 DA - 2006/12/06 TI - Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation JO - BMC Cancer SP - 277 VL - 6 IS - 1 AB - Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical responsiveness to gefitinib. However, gefitinib-sensitive and prolonged stable-disease-defined tumors without EGFR gene mutation have also been reported. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-6-277 DO - 10.1186/1471-2407-6-277 ID - Noro2006 ER -